Protagenic Therapeutics Inc. (PTIX): Market Cap to Revenue Ratio
Effective management at Protagenic Therapeutics (PTIX) ensures strict control over R&D expenses, which is confirmed by the current P/S level on the chart; captures the magnitude of this parameter. Robotic protein analysis accelerates the search for neurodegeneration treatments by minimizing manual labor. The strategy is further complemented by independent preclinical development of neuropeptides and research alliances with scientific institutes.
Protagenic Therapeutics (PTIX) - metric breakdowns and financial figures
- current quotes and average value forecast:
- stock exchange capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Protagenic Therapeutics|PTIX - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio protagenic.com|PTIX - Company Aggregate Debts|Debt to Net Assets Ratio Protagenic|PTIX - Company Long-Term Debts|Short-Term Debt Protagenic Therapeutics|Intermediate Coverage Ratio protagenic.com
- net income and valuation ratios data:
PTIX - Net Profit|Projected Future Earnings Protagenic Therapeutics|PTIX - Price to Earnings Ratio|Price to Expected Earnings Ratio protagenic.com|PTIX - PEG Multiple|Company Value to EBITDA Protagenic|PTIX - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Protagenic Therapeutics|PTIX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months protagenic.com|PTIX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Protagenic Therapeutics
- issuer revenue and sales details:
General company analysis:Protagenic Therapeutics Inc., PTIX
To filter blue-chip assets, investors must distinguish market expectations from actual operational efficiency. This indicator correlates market capitalization with annual turnover to determine the cost per unit of revenue, which, for Protagenic Therapeutics (PTIX), a company focused on preclinical neuropeptide research without external support, makes the price-to-sales chart a key tool for assessing the speculative premium attached to future discoveries.
Competing companies
BIIB - Price to Sales|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|RGC: Market Cap to Revenue Ratio|Axsome Therapeutics Inc - P/S Multiple|Price-to-Revenue Coefficient ACADIA Corp ACAD|XENE: P/S Multiple|Market Cap to Revenue vikingtherapeutics.com|Market Cap to Revenue SUPN|CPRX: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue DNLI (Denali Therapeutics Inc)|Market Cap to Sales Volume HRMY|P/S Multiple BHVN (Biohaven Ltd.)|Market Capitalization-to-Revenue Ratio AMLX|Trevi Therapeutics, Inc. - P/S Multiple|Price to Sales Praxis Precision Medicines Inc|Anavex Corp (AVXL) - Price-to-Revenue Ratio|CeriBell EEG - Market Capitalization-to-Revenue Ratio|PRTA (Prothena Biosciences) - P/S Multiple|P/S Multiple Alector Therapeutics|Price-to-Revenue Ratio Annexon (ANNX)|OMER: Price-to-Sales Ratio|P/S Multiple NGNE (Neurogene Corp)|AC Immune Inc (ACIU) - Price to Sales|VYGR: Market Cap to Revenue|NMRA - P/S Multiple|SCLX (Scilex) - Market Cap to Revenue|TVGN: Market Cap to Sales Volume|ACOG (Alpha Cognition Inc) - P/S Multiple|Cognition Therapeutics Inc. (CGTX) - Price-to-Revenue Coefficient|P/S Multiple IKT|Market Cap to Revenue cassavasciences.com SAVA|Price-to-Revenue Ratio Assertio ASRT|Price-to-Revenue Coefficient Coya Therapeutics Inc (COYA)|VTGN - Price-to-Revenue Ratio|Price-to-Sales Ratio OVID|ABOS (Acumen Pharmaceuticals) - Market Cap to Revenue|CRVO: Market Cap to Sales Volume|ATHE (Alterity Therapeutics Ltd.) - P/S Multiple|Clene Nanomedicine (CLNN) - Price-to-Revenue Coefficient|Market Cap to Revenue PEPG (PepGen Inc.)|Jupiter Neurosciences, Inc. - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Relmada Therapeutics RLMD|ANVS: Market Cap to Revenue Ratio|Grace Tx - P/S Multiple|Price to Sales Firefly Neuroscience, Inc.|KLTO (anewmeds.com) - Market Cap to Revenue|NeuroSense Therapeutics Ltd. (NRSN) - P/S Multiple|Price-to-Revenue Ratio Reviva Pharmaceuticals|MTVA: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio NeurAxis (NRXS)|HSDT - Price to Sales|Price-to-Revenue Ratio Passage Bio PASG|NEUP (Neuphoria Therapeutics, Inc.) - Price-to-Sales Ratio|NERV - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ATHA (athira.com)|Addex Therapeutics Ltd (ADXN) - Price-to-Revenue Ratio|Price to Sales Alzamend Neuro (ALZN)|Market Cap to Revenue CYCN|KTTA (Pasithea) - Market Cap to Sales Volume|P/S Multiple CRGT|P/S Multiple avenuetx.com (ATXI)|P/S Multiple BCLI (BrainStorm Cell Therapeutics)|Price-to-Revenue Multiple Cara Therapeutics Inc.|Chromocell Therapeutics Corporation - P/S Multiple|Price to Sales Eliem Therapeutics|intracellulartherapies.com (ITCI) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio LBPH|MRNS (Marinus Pharmaceuticals, Inc.) - P/S Multiple|NKGen Biotech Inc (NKGN) - Price-to-Revenue Coefficient|P/S Multiple NRBO|Market Cap to Revenue Sage Therapeutics Inc SAGE|Synaptogenix, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio TRVN|VIGL: Market Cap to Revenue|anewmeds.com - Market Cap to Sales Volume|CERE: P/S Multiple
